$ORMP
ORAMED PHARMACEUTICALS INC.

2011 Q3 Form 10-K Financial Statement

#000117891312003413 Filed on December 12, 2012

View on sec.gov

Income Statement

Concept 2011 Q3 2011 2010 Q3
Revenue $0.00 $349.7K $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $300.0K $1.280M $560.0K
YoY Change -46.43% -15.23% 69.7%
% of Gross Profit
Research & Development $290.0K $1.159M $590.0K
YoY Change -50.85% -20.6% 742.86%
% of Gross Profit
Depreciation & Amortization $10.00K $28.30K $10.00K
YoY Change 0.0% -5.66% 0.0%
% of Gross Profit
Operating Expenses $590.0K $1.159M $1.160M
YoY Change -49.14% -60.97% 190.0%
Operating Profit -$2.435M
YoY Change
Interest Expense $0.00 $1.050M $10.00K
YoY Change -100.0% 10400.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$800.0K -$1.585M -$1.150M
YoY Change -30.43% -46.45% 187.5%
Income Tax -$20.00K -$23.98K $10.00K
% Of Pretax Income
Net Earnings -$770.0K -$1.561M -$1.170M
YoY Change -34.19% -47.56% 192.5%
Net Earnings / Revenue -446.42%
Basic Earnings Per Share
Diluted Earnings Per Share -$131.6K -$287.8K -$244.3K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2011 Q3 2011 2010 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.700M $3.700M $1.300M
YoY Change 184.62% 184.62% -52.21%
Cash & Equivalents $1.513M $1.510M $1.200M
Short-Term Investments $2.190M $2.190M $100.0K
Other Short-Term Assets $20.00K $20.00K $20.00K
YoY Change 0.0% 0.0% 0.0%
Inventory
Prepaid Expenses $1.670K
Receivables $542.9K $540.0K $60.00K
Other Receivables $24.19K $30.00K $20.00K
Total Short-Term Assets $4.284M $4.280M $1.400M
YoY Change 206.01% 205.71% -55.84%
LONG-TERM ASSETS
Property, Plant & Equipment $17.38K $20.00K $40.00K
YoY Change -56.56% -50.0% -50.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $10.00K $10.00K $10.00K
YoY Change 0.0% 0.0% 0.0%
Other Assets $10.00K $10.00K $0.00
YoY Change
Total Long-Term Assets $41.86K $50.00K $50.00K
YoY Change -16.29% 0.0% -44.44%
TOTAL ASSETS
Total Short-Term Assets $4.284M $4.280M $1.400M
Total Long-Term Assets $41.86K $50.00K $50.00K
Total Assets $4.326M $4.330M $1.450M
YoY Change 198.34% 198.62% -55.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $380.0K $340.0K $410.0K
YoY Change -7.32% -10.53% 720.0%
Accrued Expenses $50.00K
YoY Change 66.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $441.3K $440.0K $460.0K
YoY Change -4.07% -4.35% 24.32%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $160.0K $160.0K $160.0K
YoY Change 0.0% 0.0% 6.67%
Total Long-Term Liabilities $160.7K $160.0K $160.0K
YoY Change 0.46% 0.0% 6.67%
TOTAL LIABILITIES
Total Short-Term Liabilities $441.3K $440.0K $460.0K
Total Long-Term Liabilities $160.7K $160.0K $160.0K
Total Liabilities $602.0K $600.0K $620.0K
YoY Change -2.9% -3.23% 19.23%
SHAREHOLDERS EQUITY
Retained Earnings -$14.55M
YoY Change
Common Stock $18.27M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.723M $3.720M $830.3K
YoY Change
Total Liabilities & Shareholders Equity $4.326M $4.330M $1.450M
YoY Change 198.34% 198.62% -55.52%

Cashflow Statement

Concept 2011 Q3 2011 2010 Q3
OPERATING ACTIVITIES
Net Income -$770.0K -$1.561M -$1.170M
YoY Change -34.19% -47.56% 192.5%
Depreciation, Depletion And Amortization $10.00K $28.30K $10.00K
YoY Change 0.0% -5.66% 0.0%
Cash From Operating Activities -$430.0K -$1.706M -$340.0K
YoY Change 26.47% 20.13% -32.0%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $2.180K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$10.00K $3.275K $400.0K
YoY Change -102.5% -99.64% -140.4%
Cash From Investing Activities -$10.00K -$1.703M $400.0K
YoY Change -102.5% -289.27% -140.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 $3.694M 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -430.0K -$1.706M -340.0K
Cash From Investing Activities -10.00K -$1.703M 400.0K
Cash From Financing Activities 0.000 $3.694M 0.000
Net Change In Cash -440.0K $284.9K 60.00K
YoY Change -833.33% -154.8% -104.0%
FREE CASH FLOW
Cash From Operating Activities -$430.0K -$1.706M -$340.0K
Capital Expenditures $0.00 $2.180K $0.00
Free Cash Flow -$430.0K -$1.708M -$340.0K
YoY Change 26.47% 20.28% -30.61%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2011 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings
-197412 USD
CY2012 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
USD
CY2011 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
581977 USD
CY2012 dei Amendment Flag
AmendmentFlag
false
CY2012 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--08-31
CY2012 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2012 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2012
CY2012 dei Document Period End Date
DocumentPeriodEndDate
2012-08-31
CY2012 dei Document Type
DocumentType
10-K
CY2012 dei Entity Central Index Key
EntityCentralIndexKey
0001176309
CY2012Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
86505020
CY2012 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2012 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2012Q1 dei Entity Public Float
EntityPublicFloat
17492586 USD
CY2012 dei Entity Registrant Name
EntityRegistrantName
ORAMED PHARMACEUTICALS INC.
CY2012 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
ormp Adjustment To Additional Paid In Capital Imputed Interest
AdjustmentToAdditionalPaidInCapitalImputedInterest
8437 USD
CY2008 ormp Adjustment To Additional Paid In Capital Imputed Interest
AdjustmentToAdditionalPaidInCapitalImputedInterest
3780 USD
CY2009 ormp Adjustment To Additional Paid In Capital Imputed Interest
AdjustmentToAdditionalPaidInCapitalImputedInterest
3780 USD
CY2010 ormp Adjustment To Additional Paid In Capital Imputed Interest
AdjustmentToAdditionalPaidInCapitalImputedInterest
3780 USD
CY2011 ormp Change In Fair Value Of Derivative Liability
ChangeInFairValueOfDerivativeLiability
USD
CY2012 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2012 ormp Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Consultants
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants
117098 USD
CY2011 ormp Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Consultants
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants
26733 USD
ormp Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Consultants
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants
177782 USD
CY2008 ormp Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Consultants
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants
203982 USD
CY2009 ormp Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Consultants
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants
117174 USD
CY2010 ormp Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Consultants
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants
116944 USD
CY2011 ormp Adjustment To Additional Paid In Capital Imputed Interest
AdjustmentToAdditionalPaidInCapitalImputedInterest
3782 USD
CY2011 ormp Business Acquisition Receivables
BusinessAcquisitionReceivables
450000 USD
CY2012 ormp Change In Fair Value Of Derivative Liability
ChangeInFairValueOfDerivativeLiability
142704 USD
ormp Change In Fair Value Of Derivative Liability
ChangeInFairValueOfDerivativeLiability
142704 USD
CY2012Q3 ormp Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
1351352
CY2011Q1 ormp Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
2187500
ormp Class Of Warrant Or Right Term
ClassOfWarrantOrRightTerm
P5Y
CY2011Q2 ormp Class Of Warrant Or Right Term
ClassOfWarrantOrRightTerm
P5Y
CY2011Q1 ormp Class Of Warrant Or Right Term
ClassOfWarrantOrRightTerm
P5Y
CY2012Q3 ormp Class Of Warrant Or Right Term
ClassOfWarrantOrRightTerm
P5Y
CY2011Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1513365 USD
CY2012 ormp Consulting Fees
ConsultingFees
159136 USD
CY2011 ormp Consulting Fees
ConsultingFees
171167 USD
ormp Consulting Fees
ConsultingFees
970900 USD
CY2012Q3 ormp Defined Contribution Plan Expected Liability
DefinedContributionPlanExpectedLiability
7619 USD
ormp Discount On Convertible Note Related To Beneficial Conversion Feature
DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature
108000 USD
CY2012 ormp Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Change In Fair Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue
142704 USD
CY2012Q3 ormp Finders Fee
FindersFee
71250 USD
CY2012 ormp Imputed Interest Expense
ImputedInterestExpense
USD
CY2011 ormp Imputed Interest Expense
ImputedInterestExpense
3782 USD
ormp Imputed Interest Expense
ImputedInterestExpense
23559 USD
CY2011 ormp Investment Before Cost
InvestmentBeforeCost
1039907 USD
CY2011 ormp Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment Realized Upon Sale Or Liquidation Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidationNetOfTax
7930 USD
CY2012 ormp Proceeds From Receipts On Account Of Shares Issuances
ProceedsFromReceiptsOnAccountOfSharesIssuances
USD
ormp Research And Development Expense Payroll And Consulting Fees
ResearchAndDevelopmentExpensePayrollAndConsultingFees
1921533 USD
CY2012 ormp Research And Development Expenses Other
ResearchAndDevelopmentExpensesOther
160350 USD
CY2011 ormp Research And Development Expenses Other
ResearchAndDevelopmentExpensesOther
49444 USD
ormp Research And Development Expenses Other
ResearchAndDevelopmentExpensesOther
547608 USD
CY2012 ormp Research And Development Expenses Share Based Compensation
ResearchAndDevelopmentExpensesShareBasedCompensation
98688 USD
CY2011 ormp Research And Development Expenses Share Based Compensation
ResearchAndDevelopmentExpensesShareBasedCompensation
265327 USD
CY2011 ormp Proceeds From Receipts On Account Of Shares Issuances
ProceedsFromReceiptsOnAccountOfSharesIssuances
USD
ormp Proceeds From Receipts On Account Of Shares Issuances
ProceedsFromReceiptsOnAccountOfSharesIssuances
6061 USD
CY2011 ormp Realized Cost Of Investment
RealizedCostOfInvestment
6903 USD
CY2008 ormp Receipts On Account Of Shares And Warrants
ReceiptsOnAccountOfSharesAndWarrants
6061 USD
CY2012 ormp Research And Development Expense Clinical Trials
ResearchAndDevelopmentExpenseClinicalTrials
1298310 USD
CY2011 ormp Research And Development Expense Clinical Trials
ResearchAndDevelopmentExpenseClinicalTrials
591733 USD
ormp Research And Development Expense Clinical Trials
ResearchAndDevelopmentExpenseClinicalTrials
5163353 USD
CY2012 ormp Research And Development Expense Payroll And Consulting Fees
ResearchAndDevelopmentExpensePayrollAndConsultingFees
385646 USD
CY2011 ormp Research And Development Expense Payroll And Consulting Fees
ResearchAndDevelopmentExpensePayrollAndConsultingFees
413191 USD
ormp Research And Development Expenses Share Based Compensation
ResearchAndDevelopmentExpensesShareBasedCompensation
2921881 USD
ormp Securities Purchase Agreement Number Of Units
SecuritiesPurchaseAgreementNumberOfUnits
9706250
CY2011Q2 ormp Securities Purchase Agreement Number Of Units
SecuritiesPurchaseAgreementNumberOfUnits
1124375
ormp Securities Purchase Agreements Number Of Shares Per Unit
SecuritiesPurchaseAgreementsNumberOfSharesPerUnit
1
CY2011Q2 ormp Securities Purchase Agreements Number Of Shares Per Unit
SecuritiesPurchaseAgreementsNumberOfSharesPerUnit
1
ormp Securities Purchase Agreements Number Of Shares Per Warrant
SecuritiesPurchaseAgreementsNumberOfSharesPerWarrant
0.35
CY2011Q2 ormp Securities Purchase Agreements Number Of Shares Per Warrant
SecuritiesPurchaseAgreementsNumberOfSharesPerWarrant
0.35
ormp Securities Purchase Agreements Number Of Warrants Per Unit
SecuritiesPurchaseAgreementsNumberOfWarrantsPerUnit
1
CY2011Q2 ormp Securities Purchase Agreements Number Of Warrants Per Unit
SecuritiesPurchaseAgreementsNumberOfWarrantsPerUnit
1
ormp Securities Purchase Agreements Purchase Price Per Unit
SecuritiesPurchaseAgreementsPurchasePricePerUnit
0.32
CY2011Q2 ormp Securities Purchase Agreements Purchase Price Per Unit
SecuritiesPurchaseAgreementsPurchasePricePerUnit
0.32
CY2012Q3 ormp Service Agreement Consideration Payable
ServiceAgreementConsiderationPayable
3500000 USD
CY2012Q3 ormp Severance Pay Insurance Deposit Expected Amount
SeverancePayInsuranceDepositExpectedAmount
10155 USD
CY2012 ormp Severance Pay Insurance Deposits
SeverancePayInsuranceDeposits
3620 USD
CY2011 ormp Severance Pay Insurance Deposits
SeverancePayInsuranceDeposits
3275 USD
CY2012Q3 ormp Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Aggregate Intrinsic Value
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsAggregateIntrinsicValue
971433 USD
CY2011Q3 ormp Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Aggregate Intrinsic Value
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsAggregateIntrinsicValue
USD
CY2012Q3 ormp Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Aggregate Intrinsic Value
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsAggregateIntrinsicValue
971433 USD
CY2011Q3 ormp Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Aggregate Intrinsic Value
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsAggregateIntrinsicValue
USD
ormp Shares Cancelled Value
SharesCancelledValue
USD
ormp Stock Issued During Period Value Offering Costs
StockIssuedDuringPeriodValueOfferingCosts
USD
CY2012 ormp Stock Issued During Period Value Services
StockIssuedDuringPeriodValueServices
107860 USD
CY2011 ormp Stock Issued During Period Value Services
StockIssuedDuringPeriodValueServices
227569 USD
ormp Stock Issued During Period Value Services
StockIssuedDuringPeriodValueServices
98750 USD
CY2008 ormp Stock Issued During Period Value Services
StockIssuedDuringPeriodValueServices
116110 USD
CY2009 ormp Stock Issued During Period Value Services
StockIssuedDuringPeriodValueServices
152928 USD
CY2010 ormp Stock Issued During Period Value Services
StockIssuedDuringPeriodValueServices
249850 USD
CY2012 ormp Weighted Average Number Of Shares Outstanding Basic And Diluted Duration
WeightedAverageNumberOfSharesOutstandingBasicAndDilutedDuration
70605814
CY2011 ormp Weighted Average Number Of Shares Outstanding Basic And Diluted Duration
WeightedAverageNumberOfSharesOutstandingBasicAndDilutedDuration
64999026
CY2012Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
597173 USD
CY2011Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
375538 USD
CY2012Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
580714 USD
CY2011Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
339052 USD
CY2012Q3 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
47252 USD
CY2011Q3 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
47252 USD
CY2012Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
87691 USD
CY2011Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
542891 USD
CY2012Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
120844 USD
CY2011Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
106107 USD
CY2012Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
21568192 USD
CY2011Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
18201111 USD
us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
108000 USD
us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
18991 USD
CY2012 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
275241 USD
CY2011 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
502593 USD
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1968547 USD
CY2008 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
459467 USD
CY2009 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
436025 USD
CY2010 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
690882 USD
CY2012 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
172470 USD
CY2011 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
263999 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2049406 USD
CY2012 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
USD
CY2011 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
108000 USD
CY2012Q3 us-gaap Assets
Assets
5294851 USD
CY2011Q3 us-gaap Assets
Assets
4325937 USD
CY2012Q3 us-gaap Assets Current
AssetsCurrent
5276476 USD
CY2011Q3 us-gaap Assets Current
AssetsCurrent
4284082 USD
CY2012Q3 us-gaap Available For Sale Securities Fair Value Disclosure
AvailableForSaleSecuritiesFairValueDisclosure
200311 USD
CY2011Q3 us-gaap Available For Sale Securities Fair Value Disclosure
AvailableForSaleSecuritiesFairValueDisclosure
384565 USD
CY2012 us-gaap Business Development
BusinessDevelopment
284899 USD
CY2011 us-gaap Business Development
BusinessDevelopment
151886 USD
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
450000 USD
CY2012 us-gaap Proceeds From Sale Of Other Investments
ProceedsFromSaleOfOtherInvestments
1800000 USD
us-gaap Business Development
BusinessDevelopment
815945 USD
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4430740 USD
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2917375 USD
CY2011 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
313727 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
4430740 USD
CY2012Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
0.5
CY2011Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
0.5
CY2012Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
0.37
CY2011Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2187500
CY2012Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2956081
CY2012Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
33910
CY2012Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2011Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2012Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2011Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2011Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2012Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
80075725
CY2011Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
70104583
CY2012Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
67819
CY2012Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
80075725
CY2011Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
70104583
CY2012Q3 us-gaap Common Stock Value
CommonStockValue
80075 USD
CY2011Q3 us-gaap Common Stock Value
CommonStockValue
70104 USD
CY2012 us-gaap Comparability Of Prior Year Financial Data
ComparabilityOfPriorYearFinancialData
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <div> <div><!--StartFragment--> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 27pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"> r.</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; text-align: left"> Reclassifications</div> </td> </tr> </table> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 81pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"> Certain figures in respect of prior years have been reclassified to conform to the current year presentation.</div> <!--EndFragment--></div> </div>
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16 USD
us-gaap Contribution Of Property
ContributionOfProperty
18991 USD
CY2012Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
USD
CY2011Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
USD
CY2012Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
3190152 USD
CY2011Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
1813108 USD
CY2012Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
3190152 USD
CY2011Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1813108 USD
CY2012 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
7089 USD
CY2011 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
6966 USD
CY2012Q3 us-gaap Deposits Assets Current
DepositsAssetsCurrent
454381 USD
CY2011Q3 us-gaap Deposits Assets Current
DepositsAssetsCurrent
1801400 USD
CY2012 us-gaap Depreciation
Depreciation
14737 USD
CY2011 us-gaap Depreciation
Depreciation
28303 USD
us-gaap Depreciation
Depreciation
120844 USD
CY2012Q3 us-gaap Due From Joint Ventures Current
DueFromJointVenturesCurrent
USD
CY2011Q3 us-gaap Due From Joint Ventures Current
DueFromJointVenturesCurrent
450844 USD
CY2012Q3 us-gaap Due From Other Related Parties Current
DueFromOtherRelatedPartiesCurrent
404 USD
CY2011Q3 us-gaap Due From Other Related Parties Current
DueFromOtherRelatedPartiesCurrent
USD
CY2012Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
USD
CY2011Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
18502 USD
CY2012 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
CY2011 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2012 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2012 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-38857 USD
CY2011 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
28789 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-10068 USD
CY2012Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
16459 USD
CY2011Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
36486 USD
CY2012 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings
USD
CY2012 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
-384565 USD
CY2011 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
USD
CY2012Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
USD
CY2011Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
384565 USD
CY2012 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
494478 USD
CY2012Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
637182 USD
CY2011Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
USD
CY2012 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
-7569 USD
CY2011 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
-33567 USD
us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
62001 USD
CY2012 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-62494 USD
CY2011 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
30791 USD
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-31037 USD
CY2012 us-gaap Foreign Income Tax Expense Benefit Continuing Operations
ForeignIncomeTaxExpenseBenefitContinuingOperations
97787 USD
CY2011 us-gaap Foreign Income Tax Expense Benefit Continuing Operations
ForeignIncomeTaxExpenseBenefitContinuingOperations
9587 USD
us-gaap Foreign Income Tax Expense Benefit Continuing Operations
ForeignIncomeTaxExpenseBenefitContinuingOperations
202755 USD
CY2012 us-gaap Gain Loss On Investments Excluding Other Than Temporary Impairments
GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments
USD
CY2011 us-gaap Gain Loss On Investments Excluding Other Than Temporary Impairments
GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments
1033004 USD
us-gaap Gain Loss On Investments Excluding Other Than Temporary Impairments
GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments
1033004 USD
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1203164 USD
CY2011 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1275960 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8161547 USD
CY2012 us-gaap General Insurance Expense
GeneralInsuranceExpense
22375 USD
CY2011 us-gaap General Insurance Expense
GeneralInsuranceExpense
23890 USD
us-gaap General Insurance Expense
GeneralInsuranceExpense
118921 USD
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-599067 USD
CY2011 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-415836 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-8440543 USD
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3254260 USD
CY2011 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1585225 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17651001 USD
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-2655193 USD
CY2011 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-1169389 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-9210458 USD
CY2012Q3 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
53341 USD
CY2011Q3 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
32406 USD
CY2012 us-gaap Income Tax Examination Penalties Expense
IncomeTaxExaminationPenaltiesExpense
15539 USD
CY2011 us-gaap Income Tax Examination Penalties Expense
IncomeTaxExaminationPenaltiesExpense
34105 USD
CY2012 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
90218 USD
CY2011 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-23980 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
240776 USD
CY2012 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
516749 USD
CY2011 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-58357 USD
us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2762468 USD
CY2012 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
502086 USD
CY2011 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
132064 USD
us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
1183796 USD
CY2012 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1138991 USD
CY2011 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-554829 USD
us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-6177851 USD
CY2012 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
120156 USD
CY2011 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
481122 USD
us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
2244091 USD
CY2012 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
90218 USD
CY2011 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
-23980 USD
us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
228272 USD
CY2012 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
203133 USD
CY2011 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-17290 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
597173 USD
CY2012 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
90218 USD
CY2011 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-36484 USD
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
228272 USD
CY2012 us-gaap Increase Decrease In Pension And Postretirement Obligations
IncreaseDecreaseInPensionAndPostretirementObligations
-2489 USD
CY2011 us-gaap Increase Decrease In Pension And Postretirement Obligations
IncreaseDecreaseInPensionAndPostretirementObligations
22675 USD
us-gaap Increase Decrease In Pension And Postretirement Obligations
IncreaseDecreaseInPensionAndPostretirementObligations
20186 USD
CY2012 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
31199 USD
CY2011 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
36105 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
160159 USD
CY2012 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
USD
CY2011 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-2407 USD
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
7509 USD
CY2012 us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
USD
CY2011 us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
-8 USD
us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
16000 USD
CY2012Q3 us-gaap Interest Bearing Deposits In Banks
InterestBearingDepositsInBanks
454381 USD
CY2011Q3 us-gaap Interest Bearing Deposits In Banks
InterestBearingDepositsInBanks
1801400 USD
CY2012Q3 us-gaap Investments And Other Noncurrent Assets
InvestmentsAndOtherNoncurrentAssets
8867 USD
CY2011Q3 us-gaap Investments And Other Noncurrent Assets
InvestmentsAndOtherNoncurrentAssets
10186 USD
CY2012 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
107860 USD
CY2011 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
227569 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1155956 USD
CY2012Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5294851 USD
CY2011Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4325937 USD
CY2012Q3 us-gaap Liabilities Current
LiabilitiesCurrent
644425 USD
CY2011Q3 us-gaap Liabilities Current
LiabilitiesCurrent
441292 USD
CY2012Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
872413 USD
CY2011Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
160729 USD
CY2012Q3 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
228272 USD
CY2011Q3 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
138054 USD
CY2012 us-gaap License Costs
LicenseCosts
110811 USD
CY2011 us-gaap License Costs
LicenseCosts
189342 USD
us-gaap License Costs
LicenseCosts
451610 USD
CY2012Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
200311 USD
CY2011Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
384565 USD
CY2012 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3488942 USD
CY2011 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3694212 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15491939 USD
CY2012 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1768898 USD
CY2011 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1703430 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-165751 USD
CY2012 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2301608 USD
CY2011 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1705844 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10885380 USD
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-3344478 USD
CY2011 us-gaap Net Income Loss
NetIncomeLoss
-1561245 USD
us-gaap Net Income Loss
NetIncomeLoss
-17891777 USD
us-gaap Net Income Loss
NetIncomeLoss
-4478917 USD
CY2008 us-gaap Net Income Loss
NetIncomeLoss
-2769271 USD
CY2009 us-gaap Net Income Loss
NetIncomeLoss
-2760474 USD
CY2010 us-gaap Net Income Loss
NetIncomeLoss
-2977376 USD
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-2884009 USD
CY2011 us-gaap Operating Income Loss
OperatingIncomeLoss
-2435269 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-18129117 USD
CY2012Q3 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
4896605 USD
CY2011Q3 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
3468280 USD
CY2012 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
127436 USD
CY2011 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
91536 USD
us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
732493 USD
CY2012 us-gaap Other Labor Related Expenses
OtherLaborRelatedExpenses
144101 USD
CY2011 us-gaap Other Labor Related Expenses
OtherLaborRelatedExpenses
174229 USD
us-gaap Other Labor Related Expenses
OtherLaborRelatedExpenses
753208 USD
CY2012Q3 us-gaap Other Liabilities Fair Value Disclosure
OtherLiabilitiesFairValueDisclosure
637182 USD
CY2012 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
199123 USD
CY2011 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
18780 USD
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
380380 USD
CY2012 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
13126 USD
CY2011 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
33232 USD
CY2011 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
3275 USD
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
6895 USD
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2129 USD
CY2012 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
USD
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
207158 USD
CY2012 us-gaap Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities
184254 USD
CY2011 us-gaap Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities
197412 USD
us-gaap Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities
381666 USD
CY2012 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
3620 USD
CY2012Q3 us-gaap Other Receivables
OtherReceivables
34350 USD
CY2011Q3 us-gaap Other Receivables
OtherReceivables
59641 USD
CY2012Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
84642 USD
CY2011Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
24191 USD
CY2012 us-gaap Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net
OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet
USD
CY2011 us-gaap Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net
OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet
USD
us-gaap Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net
OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet
434876 USD
CY2011 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2180 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
125612 USD
CY2012 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
475353 USD
CY2011 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
1700382 USD
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
5903735 USD
CY2012Q3 us-gaap Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
6959 USD
CY2011Q3 us-gaap Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
22675 USD
CY2012Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2307 USD
CY2011Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1670 USD
CY2012Q3 us-gaap Prepaid Pension Costs
PrepaidPensionCosts
4740 USD
CY2011Q3 us-gaap Prepaid Pension Costs
PrepaidPensionCosts
14293 USD
CY2011 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
275000 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
3106000 USD
CY2011Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
359800 USD
CY2012 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
3488942 USD
CY2011 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
3694212 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
15144635 USD
CY2012 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
USD
CY2011 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
120000 USD
CY2012 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
USD
CY2011 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
USD
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
66243 USD
CY2012 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
450000 USD
CY2011 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
USD
CY2011 us-gaap Proceeds From Sale Of Other Investments
ProceedsFromSaleOfOtherInvestments
USD
CY2011Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17376 USD
CY2011Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
123483 USD
CY2012Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4768 USD
us-gaap Proceeds From Sale Of Other Investments
ProceedsFromSaleOfOtherInvestments
5428000 USD
CY2012 us-gaap Professional Fees
ProfessionalFees
221218 USD
CY2011 us-gaap Professional Fees
ProfessionalFees
344277 USD
us-gaap Professional Fees
ProfessionalFees
1899744 USD
CY2012Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
125612 USD
CY2012 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
USD
CY2011 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
275000 USD
CY2012 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
USD
CY2011 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
120000 USD
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1680845 USD
CY2011 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1159309 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9532694 USD
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2012Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
16000 USD
CY2012Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
16000 USD
CY2011Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
16000 USD
CY2012Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-17870254 USD
CY2011Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-14547299 USD
CY2012 us-gaap Revenue From Grants
RevenueFromGrants
372959 USD
CY2011 us-gaap Revenue From Grants
RevenueFromGrants
349728 USD
us-gaap Revenue From Grants
RevenueFromGrants
1468290 USD
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Term Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMaximum
6
CY2012Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
0.3
CY2012 us-gaap Severance Costs
SeveranceCosts
5615 USD
CY2011 us-gaap Severance Costs
SeveranceCosts
10241 USD
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
271158 USD
CY2011 us-gaap Share Based Compensation
ShareBasedCompensation
529326 USD
us-gaap Share Based Compensation
ShareBasedCompensation
4971287 USD
CY2011Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationCost
15211 USD
CY2011Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2002Q2 us-gaap Stockholders Equity
StockholdersEquity
53700 USD
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Term Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMaximum
10
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Term Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMinimum
5
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Term Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMinimum
5
CY2011Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.135
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7603
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.142
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7603
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.125
CY2011Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0209
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.01
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.036
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.008
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.016
CY2011 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3694212 USD
CY2011Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
0.63
CY2012Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm1
2.74
CY2011Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm1
5.39
CY2012Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
8925359
CY2011Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
606200
CY2012Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
10009360
CY2011Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
988200
CY2012Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
0.21
CY2011Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
0.6
CY2012Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm1
3.18
CY2011Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm1
6.06
CY2012Q3 us-gaap Stockholders Equity
StockholdersEquity
3778013 USD
CY2011Q3 us-gaap Stockholders Equity
StockholdersEquity
3723916 USD
CY2010Q3 us-gaap Stockholders Equity
StockholdersEquity
830272 USD
CY2007Q3 us-gaap Stockholders Equity
StockholdersEquity
513131 USD
CY2008Q3 us-gaap Stockholders Equity
StockholdersEquity
4593060 USD
CY2009Q3 us-gaap Stockholders Equity
StockholdersEquity
2746132 USD
CY2011 us-gaap Stock Issued1
StockIssued1
76026 USD
us-gaap Stock Issued1
StockIssued1
77779 USD
CY2011 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
581977 USD
CY2008 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
275000 USD
CY2012 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2851760 USD
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2122981 USD
CY2008 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5784800 USD
us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
434876 USD
CY2012 us-gaap Travel And Entertainment Expense
TravelAndEntertainmentExpense
71529 USD
CY2011 us-gaap Travel And Entertainment Expense
TravelAndEntertainmentExpense
54976 USD
us-gaap Travel And Entertainment Expense
TravelAndEntertainmentExpense
545930 USD
CY2012Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
228272 USD
CY2011Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
138054 USD
CY2010Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
162034 USD
CY2012 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
90218 USD
CY2011 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
-23980 USD
CY2012 us-gaap Use Of Estimates
UseOfEstimates
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <div> <div><!--StartFragment--> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 54pt">&nbsp;</td> <td style="WIDTH: 27pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"> c.</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; text-align: justify"> Use of estimates in the preparation of financial statements</div> </td> </tr> </table> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 90pt; MARGIN-RIGHT: -0.05pt; text-align: left; TEXT-INDENT: 0pt"> <br /> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 81pt; MARGIN-RIGHT: -0.05pt; text-align: left; TEXT-INDENT: 0pt"> The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the financial statements date and the reported expenses during the reporting periods. Actual results could differ from those estimates.</div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 81pt; MARGIN-RIGHT: -0.05pt; text-align: left; TEXT-INDENT: 0pt"> As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to stock based compensation, valuation and impairment of marketable securities and valuation of tax exposure.</div> <!--EndFragment--></div> </div>
CY2012Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
637182 USD
CY2011Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
USD

Files In Submission

Name View Source Status
0001178913-12-003413-index-headers.html Edgar Link pending
0001178913-12-003413-index.html Edgar Link pending
0001178913-12-003413.txt Edgar Link pending
0001178913-12-003413-xbrl.zip Edgar Link pending
exhibit_10-19.htm Edgar Link pending
exhibit_10-20.htm Edgar Link pending
exhibit_10-21.htm Edgar Link pending
exhibit_10-22.htm Edgar Link pending
exhibit_10-23.htm Edgar Link pending
exhibit_10-7.htm Edgar Link pending
exhibit_10-8.htm Edgar Link pending
exhibit_21-1.htm Edgar Link pending
exhibit_23-1.htm Edgar Link pending
exhibit_23-2.htm Edgar Link pending
exhibit_31-1.htm Edgar Link pending
exhibit_31-2.htm Edgar Link pending
exhibit_32-1.htm Edgar Link pending
exhibit_32-2.htm Edgar Link pending
exhibit_4-4.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
logo.jpg Edgar Link pending
logo2.jpg Edgar Link pending
logo3.jpg Edgar Link pending
logo4.jpg Edgar Link pending
ormp-20120831.xml Edgar Link completed
ormp-20120831.xsd Edgar Link pending
ormp-20120831_cal.xml Edgar Link unprocessable
ormp-20120831_def.xml Edgar Link unprocessable
ormp-20120831_lab.xml Edgar Link unprocessable
ormp-20120831_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
zk1212365.htm Edgar Link pending